Summary PurposeTo analyze the clinical outcome of treatment with aflibercept in patients not responding to ranibizumab and bevacizumab. MethodsRetrospective review of 32 eyes from 30 consecutive patients with choroidal neovascularization (CNV) who showed no response to treatment with ranibizumab or bevacizumab and were switched to aflibercept. Visual acuity, central macular thickness (CMT) and presence or absence of intraretinal or subretinal fluid were analyzed before switching to aflibercept, after each of three uploading dose injections of aflibercept and 6, 8 and 10 weeks after the third aflibercept injection. All eyes had previous ranibizumab injections and the mean number of previous injections was 14.75 (± 7.38). Mean duration of previous anti-vascular endothelial growth factor (VEGF) treatment was 38 months (± 27.35 months). ResultsMean visual acuity before switching to aflibercept was 0.40 ± 0.30 logMAR. After the third injection visual acuity was 0.3 ± 0.3 logMAR and 10 weeks after the third injection it was 0.50 ± 0.20 logMAR. No significant differences were seen during treatment and follow-up. The mean CMT was 394 ± 118 µm at baseline, at follow-up (first, second and third, group week 6, group week 8 and group week 10) it was 317 ± 108 µm, 301 ± 99 µm, 292 ± 83 µm, 270 ± 78 µm, 340 ± 146 µm and 377 ± 92 µm, respectively. Significant reductions in CMT were seen between the first and third follow-up injections and at group week 8. Of the patients 59.4 �ere complete non-responders to aflibercept. ConclusionAflibercept results in improvement in CMT in non-responders to ranibizumab and bevacizumab as long as therapy is given continuously and can therefore be an alternative therapy.
µm                  0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

logMAR                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/LogMAR_chart          

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

choroidal neovascularization  0.9999900176974565^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Choroidal_neovascularization

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

logMAR                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/LogMAR_chart          

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

CMT                           0.999989832048721^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Country_Music_Television

VEGF                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

alternative therapy           0.9998895778396177^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Alternative_medicine  

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

CMT                           0.999989832048721^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Country_Music_Television

CMT                           0.999989832048721^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Country_Music_Television

logMAR                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/LogMAR_chart          

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

endothelial                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Endothelium           

macular                       0.9999999999633928^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Macula_of_retina      

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

CMT                           0.999989832048721^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Country_Music_Television

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

CNV                           0.9999999611320626^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Copy-number_variation 

Visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

µm                            0.9986846263856987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

aflibercept                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aflibercept           

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

